Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | METAP2 | P50579 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18497405 | 0.89 | HRH3 (0.46) | POLBL3MBTL1HRH3METAP2ALDH1A1 | |
| SCHEMBL18497373 | 0.89 | HRH3 (0.46) | POLBL3MBTL1HRH3METAP2ALDH1A1 | |
| SCHEMBL18497376 | 0.89 | HRH3 (0.46) | POLBL3MBTL1HRH3METAP2ALDH1A1 | |
| Formic Acid SCHEMBL18578982 | 0.84 | HRH3 (0.42) | POLBL3MBTL1HRH3METAP2ALDH1A1 | |
| SCHEMBL18497371 | 0.80 | POLB (0.40) | CYP1A2CYP2D6POLBL3MBTL1HRH3 | |
| SCHEMBL18497313 | 0.80 | POLB (0.40) | CYP1A2CYP2D6POLBL3MBTL1HRH3 | |
| SCHEMBL18497312 | 0.80 | POLB (0.40) | CYP1A2CYP2D6POLBL3MBTL1HRH3 | |
| SCHEMBL18497425 | 0.79 | HRH3 (0.37) | HRH3METAP2LMNA | |
| SCHEMBL18497648 | 0.79 | HRH3 (0.37) | HRH3METAP2LMNA | |
| SCHEMBL18497423 | 0.79 | HRH3 (0.37) | HRH3METAP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407946-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2008-08-05 | — | — | US | disclosed |
| US-20060058523-A1 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| EP-1575946-A1 | QUINAZOLINE COMPOUNDS | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004058752-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058523-A1 | Quinazoline compounds | NDUFS5, ABL1, NDUFS7 | CYP1A2 79/4885CYP2D6 62/4885POLB 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.